Trial intelligence / Profile preview

Carfilzomib-based induction, autologous transplant, and post-transplant consolidation for newly diagnosed multiple myeloma

ACTRN12615000188538Phase 2Active, not recruiting

Sponsor
North Shore Haematology Clinical Trial Unit
Start
Dec 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2 trial of carfilzomib, cyclophosphamide, dexamethasone and thalidomide, sponsored by North Shore Haematology Clinical Trial Unit. Started Dec 2016; status: active, not recruiting.

02

Drugs

carfilzomibcyclophosphamidedexamethasonethalidomide

Beyond the preview

Go deeper on ACTRN12615000188538.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12615000188538.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call